Effect of Early Treatment with Ivermectin among Patients with Covid-19
This page documents how this source is reused across Claim by Claim. A source can support, challenge, qualify or contextualize different claims; appearing here does not imply endorsement of every linked proposition.
Evidence roles describe what this source helps establish inside each Investigation. They are local to that use, not permanent labels attached to the publication itself.
The double-blind TOGETHER platform trial did not show a prespecified clinically meaningful reduction in hospitalization or prolonged emergency observation with ivermectin.
Intention-to-treat composite hospitalization OR >6-hour emergency observation was 100/679 (14.7%) vs 111/679 (16.3%), RR 0.90 (95% Bayesian credible interval 0.70–1.16); it did not establish a clinically meaningful benefit and is not a mortality-only outcome.